PARP Inhibitor + SOC Improves rPFS in HRR-Altered mCSPC in AMPLITUDE Trial

First Look With ASCO Daily News presents Dr. Dana Rathkopf of Memorial Sloan Kettering Cancer Center on the results of the phase 3 AMPLITUDE trial on the efficacy and safety of niraparib and abiraterone acetate plus prednisone for patients with HRR–altered metastatic castration-sensitive prostate cancer. Read the full abstract (LBA5006) from the 2025 ASCO Annual Meeting: https://meetings.asco.org/abstracts-presentations/243837 For more on ASCO25, visit https://dailynews.ascopubs.org/meetings/asco-annual-meeting _Data as of May 5, 2025_

Video Lainnya